http://www.biospace.comBioSpace RSS GeneratorWed, 19 Jun 2013 00:08:48 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130617005554&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>LUGANO, Switzerland--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study (Study 101-09) evaluating idelalisib (formerly GS-1101...Mon, 17 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=300037&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behets Disease</font></b><br><br>BOUDRY, Switzerland--(BUSINESS...Fri, 14 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299898&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis</font></b><br><br...Thu, 13 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/12/553602/0/en/TEVA-AND-ACTIVE-BIOTECH-REPORT-POSITIVE-RESULTS-FROM-PHASE-IIa-STUDY-OF-LAQUINIMOD-IN-ACTIVE-LUPUS-NEPHRITIS.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Jerusalem, Israel and Lund, Sweden, June 12(th), 2013 - Teva PharmaceuticalIndustries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI)announced today the results of a Phase IIa...Wed, 12 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/11/553449/10036033/en/Biota-Initiates-Phase-2-Trial-of-Laninamivir-Octanoate-for-the-Treatment-of-Influenza-in-Adults.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>ATLANTA, June 11, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that it has commenced dosing in a multi-national, randomized, double blind, placebo controlled...Wed, 12 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299657&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div class"xn-content"><p><span class"xn-location">EXTON, Pa.</span>, <span class"xn-chron">June 11, 2013</span> /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission...Tue, 11 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/11/553173/10035915/en/Bionomics-Completes-Enrolment-for-BNC105-Phase-II-Renal-Cancer-Trial.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>ADELAIDE, South Australia, June 10, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) has completed enrolment into a randomized Phase II clinical trial testing the combination of BNC105 plus everolimus ...Tue, 11 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/10/553043/10035705/en/Trigemina-Initiates-Phase-II-Clinical-Trial-of-TI-001-for-Chronic-Migraine.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>SANTIAGO, Chile, June 10, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced...Mon, 10 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299562&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - June 10, 2013) - BrainStorm Cell Therapeutics (OTCQB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerBCLI">BCLI...Mon, 10 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130610006187&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, announces the...Mon, 10 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/05/552179/10035316/en/RedHill-Biopharma-Commences-Patient-Screening-in-a-Phase-IIa-Clinical-Trial-With-RHB-104-for-Multiple-Sclerosis.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>TEL-AVIV, Israel, June 5, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development...Wed, 05 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130604007099&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>STOCKHOLM--(BUSINESS WIRE)--Regulatory News: NeuroVive Pharmaceutical AB (publ)(STO:NVP), a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the...Wed, 05 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299169&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - June 05, 2013) - BrainStorm Cell Therapeutics (OTCQB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerBCLI">BCLI...Wed, 05 Jun 2013 12:00:00 AM GMTStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><b><font size"3">Pluristem to Receive Clinical-hold Notice From the U.S. FDA</font></b><br><br>Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies...Tue, 04 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/03/551553/0/en/Active-Biotech-s-project-ANYARA-improved-overall-survival-in-a-subgroup-of-renal-cell-cancer-patients.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Lund (Sweden), June 3, 2013. Active Biotech (NASDAQ OMX NORDIC: ACTI) todaypresented overall survival (OS) and Progression Free Survival (PFS) data fromthe ANYARA Phase II/III study in renal cell...Mon, 03 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/03/551569/0/en/EXINI-and-Active-Biotech-present-impact-of-tasquinimod-on-bone-metastases-as-measured-by-Bone-Scan-Index-BSI.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>EXINI Diagnostics AB (NASDAQ OMX First North: EXINI) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented Phase II retrospective follow-up data from the prostate cancer project with tasquinimod combined...Mon, 03 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=298541&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Diso</font></b><br><br>HOLLYWOOD, Fla. & DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NAS: ALKS...Fri, 31 May 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/05/30/550776/0/en/An-all-oral-combination-phase-II-study-of-Simeprevir-and-Samatasvir-IDX719-for-the-treatment-of-hepatitis-C-virus-infection-initiated.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Stockholm, Sweden Medivir AB (OMX: MVIR) today announced that IdenixPharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1,evaluating an all-oral, direct-acting antiviral (DAA) HCV...Thu, 30 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130530005723&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>HUDDINGE, Sweden & STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX: MVIR) today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1, evaluating an...Thu, 30 May 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130528Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>by Richard Daverman, PhD</p><p>May 28, 2013 -- Aslan Pharmaceuticals Pte reported that ASLAN001 was effective in a Phase II trial among heavily pre-treated gastric cancer patients. ASLAN001, a small-molecule...Wed, 29 May 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/05/29/550304/0/en/Bavarian-Nordic-s-CV-301-Cancer-Immunotherapy-Candidate-Shows-Promise-in-Colorectal-Cancer.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>KVISTGAARD, Denmark, May 29, 2013 - Bavarian Nordic A/S (OMX: BAVA) announcedtoday that promising data from a Phase 2 trial of its CV-301 cancerimmunotherapy candidate in patients with resected metastatic...Wed, 29 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297348&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine</font></b><br><br>PARIS</span> and <span class"xn...Thu, 23 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130523005477&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the Company, We or Lightlake), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists...Thu, 23 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297459&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>21 May 2013 -- Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treatrespiratory diseases, today announces that a further poster was presented on Tuesday...Tue, 21 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130521006455&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs...Tue, 21 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297126&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>May 17, 2013 Safety results from Auris Medicals clinical development of AM-101 presented at international conferenceKey safety outcomes from Auris Medicals clinical development of AM-101, a novel intratympanic...Fri, 17 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=296955&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>May 16, 2013 -- Verona Pharma plc (AIM: VRP), the drug development company focused on"first-in-class" medicines to treat respiratory diseases, today announces thatthree posters will be presented at the upcoming...Thu, 16 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297034&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>LUND, SWEDEN--(Marketwired - May 16, 2013) - Active Biotech (NASDAQ OMX NORDIC: ACTI) willpresent data from two of its oncology projects, the drug candidatestasquinimod...Thu, 16 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=296808&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Lille (France), Boston (Massachusetts, United States), May 15, 2013 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on...Wed, 15 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=296452&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>MARTINSRIED / MUNCHEN, GERMANY--(Marketwired - May 13, 2013) - <p>MorphoSys AG /MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin'sLymphoma...Mon, 13 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=296285&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>TURKU, FINLAND--(Marketwired - May 10, 2013) - BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 May 2013 at 9.00 a.m.<p><b>Biotie announces start of clinical study with nepicastat...Fri, 10 May 2013 12:00:00 AM GMTStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Copenhagen, Denmark; May 1, 2013 Genmab A/S (OMX: GEN) announced today top-line results from a Phase II study of ofatumumab in combination with bendamustine in patients with untreated or relapsed chronic lymphocytic...Tue, 07 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.b30484b92e958b11adda3242e6908a0c/index.jsp?ndmViewId=news_view&newsId=20130507005886&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>DUBLIN--(BUSINESS WIRE)--Opsona Therapeutics Ltd (Opsona), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases, today announced...Tue, 07 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294686&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>April, 2013 -- Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces the formation of a Clinical and Scientific...Mon, 29 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294575&full=1<div id"releaseBody"><p>MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwired - April 26, 2013) - MorphoSys AG /MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in B-cell AcuteLymphoblastic Leukemia.<p>Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.<p>MorphoSys AG (FSE: MOR; Prime Standard...Fri, 26 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294051&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>AMSTERDAM</span>, <span class"xn-chron">April 23, 2013</span> /PRNewswire/ -- (NYSE: ABBV) Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs...Thu, 25 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294394&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump, a novel technology for the sustained production and delivery...Thu, 25 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294124&full=1<div id"releaseBody"><p>MECHELEN, BELGIUM--(Marketwired - April 23, 2013) - Galapagos NV (EURONEXT BRUSSELS: GLPG)announced todaythe start of the first Phase 2 clinical study with GLPG0974. This is thethirdcompound from Galapagos' pipeline to enter Phase 2 studies, and its firstdrugfor patients with gastro-intestinal inflammation. GLPG0974 presents anovelmode of action...Tue, 23 Apr 2013 12:00:00 AM GMThttp://www.reuters.com/article/2013/04/19/us-anaemia-pill-idUSBRE93I0GH20130419Japan's Astellas Pharma and Britain's GlaxoSmithKline are competing to develop a new kind of medicine that boosts production of red blood cells by making the body think it is at high altitude. Their experimental drugs - both given as pills - could create a major new market in treating anemia and other serious conditions, including circulatory problems and wound damage. They may also attract unscrupulous...Mon, 22 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293929&full=1Lund, Sweden 22 April 2013 - BioInvent International (OMXS:BINV) announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma. The study is conducted in patients with asymptomatic myeloma (called smoldering multiple myeloma). Smoldering myeloma patients have not developed symptoms of disease and the condition...Mon, 22 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293985&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>LEUVEN, BELGIUM--(Marketwired - April 22, 2013) - TiGenix (EURONEXT BRUSSELS: TIG), the European leader in cell therapy, today announced positive 6-month safety data of its...Mon, 22 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293987&full=1<div id"releaseBody"><p>MECHELEN, BELGIUM--(Marketwired - April 22, 2013) - <p> * GLPG1790 has high efficacy against triple-negative breast cancer<p> * Innovative, targeted approach<p> * Galapagos plans to initiate clinical trials within one year<p>Galapagos NV (EURONEXT BRUSSELS: GLPG) announced todaythat it developed GLPG1790, a novel candidate drug to treat breast...Mon, 22 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293500&full=1DUBLIN--(BUSINESS WIRE)-- Alkermes plc (ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression. ALKS 5461 reflects a new approach to the treatment of MDD based on modulation of opioid receptors in the brain and is...Wed, 17 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293517&full=1LONDON, UK, April 16, 2013 Following the widely publicised US Centers for Disease Control and Prevention report in February that the current seasons flu vaccine is only 9% effective in the over-65 population, Immune Targeting Systems Limited (ITS), today announces positive data from a Phase 2a trial with the Companys lead pan-strain influenza A T-cell vaccine, FlunisynTM, in the elderly population...Wed, 17 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293405&full=1<div id"releaseBody"><p>MECHELEN, BELGIUM--(Marketwired - April 16, 2013) - <p><br> * AbbVie provides additional funding of $20 million to Galapagos forPhase 2b program expansion<p> * Phase 2b program in RA to include 875 patients<p>Galapagos NV (Euronext: GLPG) announced anexpansion of the Phase 2b program with GLPG0634 in rheumatoid arthritis(RA).Galapagos wil...Tue, 16 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293059&full=1Washington, USA / Vienna, Austria, April 11, 2013 / B3C newswire / - Glioblastoma multiforme (GBM) is the most severe form of brain cancer and progresses rapidly. With the first-line treatment (surgery, chemo-, and radiotherapy) the prognosis is poor with a median survival rate of 14 to 15 months. This makes novel treatment strategies highly warranted. One such strategy is cancer immunotherapy (CIT...Thu, 11 Apr 2013 12:00:00 AM GMThttp://www.thestreet.com/story/11891228/1/hey-sarepta-investors-glaxos-drisapersen-data-revealed-early.htmlGlaxoSmithKline Plc (GSK)s drisapersen achieved the primary objective of a mid-stage study, heating up competition with Sarepta Therapeutics Inc. (SRPT) in the race for a drug that could reverse the debilitating effects of Duchenne muscular dystrophy. Patients taking drisapersen showed a clinically meaningful difference from those on placebo after 48 weeks of treatment, according to an abstract of...Wed, 10 Apr 2013 12:00:00 AM GMTLaboratorios SALVAT S.A. (SALVAT) and Kwang Dong Pharmaceutical Co. Ltd (Kwang Dong) today announced the successful completion of the Phase IIb clinical trial for Tarafenacin, a new drug under development for the treatment of Overactive Bladder syndrome (OAB).</p><p> In this Phase IIb trial, Tarafenacin, at doses of 0.2 mg and 0.4 mg, proved superior to placebo after 4 weeks in reducing the number...Wed, 10 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292972&full=1Oslo, Norway, April 10, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces positive final results of the phase 2b study of Cevira in patients with human papilloma virus (HPV) related disease of the cervix. Cevira, a novel and easy to use integrated drug-delivery device, demonstrated significant and sustained efficacy...Wed, 10 Apr 2013 12:00:00 AM GMThttp://www.reuters.com/article/2013/04/04/merrimack-study-cancerdrug-idUSL3N0CR2FT20130404Merrimack Pharmaceuticals Inc said one of three patient groups in a mid-stage trial of its experimental lung cancer drug failed to meet the main goal of improving survival rates after four months of treatment without the disease worsening. The company's shares fell 7 percent in premarket trade. The group was administered the drug, MM-121, in combination with erlotinib, an approved cancer treatment...Fri, 05 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292409&full=1Melbourne Australia; 3 April 2013 Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) today announced the positive results of its exploratory Phase 2 study of VivaGel for the prevention of recurrent bacterial vaginosis (R-BV). The results showed a reduced overall risk of R-BV during the study in patients using 1% VivaGel and time to first recurrence was delayed compared with placebo. </p><p>The...Thu, 04 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292264&full=1STOCKHOLM, April 2, 2013. Axelar AB, part of the Karolinska Development AB portfolio, announced today that preliminary interim results of its Phase II study AXL-003, indicates that AXL1717 is effective in treating patients with non-small cell lung cancer (NSCLC). Thus, the company assesses that it has sufficient data to guide further development of the drug, and will finalize the study with fewer patients...Wed, 03 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292271&full=1Tel Aviv, Israel, April 3, 2013 / B3C newswire / - Aspireo Pharmaceuticals Limited (Aspireo), an Israeli biopharmaceutical company, focused on the development of Somatoprim, a novel somatostatin analog (SSA), today announced results of a phase IIa study in acromegaly patients. The study was designed to investigate the safety, tolerability and efficacy of single ascending doses of Somatoprim (DG...Wed, 03 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292292&full=1<div id"releaseBody"><p>MELBOURNE, AUSTRALIA--(Marketwired - April 03, 2013) - <b> Prana Biotechnology</b> (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerPRAN">PRAN</a>) (ASX: PBT) today reported on the progress of its lead development asset PBT2 in Phase II trials for Huntington disease and Alzheimer's disease. Across the two trials approximately 37% have been dosed to 6 months...Wed, 03 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291690&full=1Cambridge, UK, 27th March 2013: Convergence Pharmaceuticals Limited (Convergence), the company focused on the development of novel analgesic medicines for the treatment of chronic pain, today announces positive interim data from the ongoing Phase II clinical trial of novel sodium channel blocker CNV1014802 in patients with trigeminal neuralgia (TN), a very severe form of facial pain. </p><p>CNV...Wed, 27 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291718&full=1<div id"releaseBody"><p>MECHELEN, BELGIUM--(Marketwire - March 27, 2013) - <p><br> * Positive Phase 1 study showed clean safety data and strong response of biomarker<p> * Phase 2a Proof of Concept study in ulcerative colitis will start nextmonth<p>Galapagos NV (Euronext: GLPG) announced todaythat GLPG0974, an inhibitor of FFA2 (free fatty acid receptor 2, formerlyknown...Wed, 27 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130327005319&newsLang=enLONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the Company or Lightlake), an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Companys Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation...Wed, 27 Mar 2013 12:00:00 AM GMThttp://www.reuters.com/article/2013/03/20/malaria-vaccine-gsk-idUSL6N0CBLHN20130320Optimism over the new malaria vaccine being tested in Africa could be set to fall after results suggested its effect could reduce over time and that it disappears fastest in children who are most exposed to malarial mosquito bites. Scientists point out that they will need to see the full results, from large-scale trials of thousands of children, before they really know how useful the vaccine developed...Fri, 22 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291335&full=1<div id"releaseBody"><p>PLAN-LES-OUATES GENEVA, SWITZERLAND--(Marketwire - March 21, 2013) - <p><br>Addex Therapeutics /<p>Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a StudyResultsat the 2013 Annual Meeting of the American Academy of Neurology (AAN)<p>Processed and transmitted by Thomson Reuters ONE.<p>The issuer is solely responsible for the content...Fri, 22 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291221&full=1<div id"releaseBody"><p>TURKU, FINLAND--(Marketwire - March 21, 2013) - Biotie announced today that full data from a Phase 2b study evaluating tozadenant (SYN115) in Parkinson's disease (PD) patients experiencing levodopa related end of dose wearing off were presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, March 20, 2013. These data were selected...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291226&full=1<div id"releaseBody"><p>NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwire - March 21, 2013) - BrainStorm Cell Therapeutics (OTCQB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerBCLI">BCLI</a>), a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company's NurOwn&#8482; technology...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130320006314&newsLang=enIRVINE, Calif. & KIEL, Germany--(BUSINESS WIRE)--Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Elafin for the prevention of inflammatory complications of transthoracic esophagectomy. Transthoracic esophagectomy is a surgical procedure that potentially offers a cure for...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291278&full=1Oxford, UK, 21 March 2013 Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy (DMD) and C. difficile infections, today outlines its future plans for the continued development of utrophin modulators for the treatment of DMD. Utrophin modulation is a disease modifying approach that has the potential to treat all genetic forms of DMD. Summit...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290622&full=1Basel, March 15, 2013 - Novartis announced today that its investigational compound LDK378 has received Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK) metastatic non-small cell lung cancer (NSCLC) who had progressed during treatment with, or were intolerant to, crizotinib. There are limited treatment...Tue, 19 Mar 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130318by Richard Daverman, PhD</p><p>March 18, 2013 -- Lipotecan, an innovative liver cancer drug developed by Taiwan Liposome Company, was accepted into the SFDAs Green Path program, a fast-track approval process. TLC said Lipotecan is a new chemical entity with multiple mechanisms of action against tumors that has shown positive results in ex-China Phase II trials. TLC expects to start a China Phase...Tue, 19 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290769&full=1<div id"releaseBody"><p>NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwire - March 18, 2013) - BrainStorm Cell Therapeutics (OTCQB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerBCLI">BCLI</a>), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Mayo Clinic in Rochester, Minnesota has entered into a Memorandum of Understanding with...Mon, 18 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290591&full=1Marseille, France, March 13, 2013 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology, announces today the initiation of a phase 1b study of olesoxime in multiple sclerosis (MS) patients as a complementary therapy to their treatment with interferon beta.</p><p>The clinical trial is designed...Thu, 14 Mar 2013 12:00:00 AM GMThttp://www.webmd.com/alzheimers/news/20130311/experimental-alzheimers-drug-shows-promise-study-findsIn patients with moderate Alzheimer's disease, an experimental drug that alters the brain's "fight or flight" impulse succeeded in improving memory modestly when it was added to at least one of the medications already in wide use to treat the memory-robbing disease. Compared with subjects taking the drug memantine and a placebo, subjects supplementing their customary drug regimen for three months with...Tue, 12 Mar 2013 12:00:00 AM GMThttp://www.pharmatimes.com/Article/13-03-11/New_anti-inflammatory_causes_stir_at_ACC.aspxA single dose of the investigational anti-inflammatory inclacumab, developed by Roche and Genmab, considerably reduces damage to heart muscle during angioplasty. That was the conclusion of a Phase II trial, the data for which has been presented at the American College of Cardiology meeting in San Francisco. The 530-patient study, led by Jean-Claude Tardif of the University of Montreal, compared the...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290108&full=1Bioggio, Switzerland, 11 March 2013 - Telormedix, a clinical stage biopharmaceutical company focusing on toll-like receptor 7 (TLR7) small molecules in the treatment of cancer and inflammatory diseases, today announced that it has recruited the first patient in a Phase II trial of its lead product TMX-101, a TLR-7 agonist, in carcinoma in situ (CIS) in the bladder. </p><p>The planned Phase II study...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289913&full=1<div id"releaseBody"><p>MELBOURNE, AUSTRALIA--(Marketwire - March 08, 2013) - <b> Prana Biotechnology </b>(NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerPRAN">PRAN</a>) (ASX: PBT). Following on from the announcement released on 4th March, 2013 and at the request of the Australian Securities Exchange, the company is pleased to provide further detail in respect to the presentation...Fri, 08 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289662&full=1<div id"releaseBody"><p>TOKYO--(Marketwire - March 06, 2013) - SymBio Pharmaceuticals Limited (JASDAQ: 4582) announced the completion of patient enrollment of its Phase II clinical trial of TREAKISYM&#174; (bendamustine hydrochloride, SyB L-0501) in frontline low-grade non-Hodgkin's lymphoma (NHL)(1) and mantle cell lymphoma (MCL) patients in Japan. This randomized trial is evaluating the combination...Wed, 06 Mar 2013 12:00:00 AM GMTSTOCKHOLM, Mar 04, 2013 (BUSINESS WIRE) -- Regulatory News: Medivir AB (sto:MVIR-B) today announced first interim results from the cohort 1 of a Phase IIa study of the investigational protease inhibitor simeprevir (TMC435) administered once daily with Gilead's investigational nucleotide inhibitor sofosbuvir (GS-7977) with and without ribavirin for 12 and 24 weeks in genotype 1 prior null-responder...Tue, 05 Mar 2013 12:00:00 AM GMThttp://www.thestreet.com/story/11854354/1/glaxo-dmd-drug-tied-to-serious-side-effects-hospitalizations.html?puc=yahoo&cm_ven=YAHOODuchenne muscular dystrophy patients treated with GlaxoSmithKline's (GSK_) experimental drug drisapersen have been hospitalized due to kidney toxicity and low platelet counts, according to a Glaxo scientist who spoke at a research meeting in Rome last Sunday. Glaxo has disclosed some safety data from early-stage drisapersen clinical trials previously, mainly related to moderate cases of proteinuria...Mon, 04 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289287&full=1<div id"releaseBody"><p>MELBOURNE, AUSTRALIA--(Marketwire - March 04, 2013) - <b>Prana Biotechnology </b>(NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerPRAN">PRAN</a>) (ASX: PBT) today announced the upcoming presentation of new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive...Mon, 04 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130304005006&newsLang=enOXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia. The agents unique dual mode of action, which has both anti-catabolic and pro-anabolic activity, directly impacts two of the principle pathophysiological...Mon, 04 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289380&full=1Oxford, 4 March 2013 Chroma Therapeutics Limited announced today that The Lancet Oncology has published the results of the OPAL Study, a Phase 2 study of two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (AML). Tosedostat is a novel, oral aminopeptidase inhibitor which deprives tumour cells of the amino acid building blocks they...Mon, 04 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289006&full=1<div id"releaseBody"><p>SYDNEY, AUSTRALIA--(Marketwire - February 27, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerPBMD">PBMD</a>) (ISIN: US74154B2034) ("Prima," the "Company") is pleased to announce that it has commenced recruitment of patients into the CANVAS (<b>CAN</b>cer <b>VA</b>ccine <b>S</b>tudy) trial in Europe. Prima has authorized...Thu, 28 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289058&full=1Marseille, France, February 27, 2013 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announces today the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).</p><p...Thu, 28 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=288726&full=1Amsterdam, The Netherlands, February 26, 2013 / B3C newswire / Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today it has received the No Objection Letter from Health Canada for its new clinical study with ATIR. This study will be a Phase II international multi-center study with clinical sites in Canada and Belgium. Up to 23 patients...Tue, 26 Feb 2013 12:00:00 AM GMT